Results 71 to 80 of about 6,429 (163)
‘BJUI Clinical Dilemma’: Recurrent high‐grade non‐muscle‐invasive bladder cancer in 2026
BJU International, Volume 138, Issue 1, Page 14-21, July 2026.
Vignesh T. Packiam +10 more
wiley +1 more source
Theranostic Advancements in Brain Cancer: Promising Approaches for Emerging Therapy
MedComm – Oncology, Volume 5, Issue 2, June 2026.Strategies for improving intra‐arterial administration (A) and photodynamic therapy in brain cancer (B). Improving intra‐arterial (IA) administration and photodynamic therapy (PDT) for brain cancer involves enhancing tumor targeting and breaching the blood–brain barrier (BBB). Key strategies include super selective catheterization, using osmotic agents
Bipraban Khanra, Manoj Kumar Sarangi
wiley +1 more source
Advanced Healthcare Materials, Volume 15, Issue 18, 15 May 2026.Cerebral organoids are transforming brain research, yet the field remains fragmented. This comprehensive systematic review maps 738 studies published between 2014 and 2024 to uncover trends, gaps, and opportunities across neuroscience. Introducing OrganoidMap—an interactive, open‐access platform to explore and compare models—this work enables ...
Anna Wolfram +10 more
wiley +1 more source
SpatialESD: Spatial Ensemble Domain Detection in Spatial Transcriptomics
Advanced Science, Volume 13, Issue 30, 28 May 2026.ABSTRACT Spatial transcriptomics (ST) measures gene expression while preserving spatial context within tissues. One of the key tasks in ST analysis is spatial domain detection, which remains challenging due to the complex structure of ST data and the varying performance of individual clustering methods. To address this, we propose SpatialESD, a Spatial
Hongyan Cao +11 more
wiley +1 more source
CellsOncolytic viruses represent an emerging class of therapeutic agents that have the potential to transform the care of patients with melanoma. In this narrative review, we describe the evolution of oncolytic virus approaches.
John Smestad +3 more
doaj +1 more source
Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors
CNS Oncology, 2013 Oncolytic viruses, such as the oncolytic herpes simplex virus (oHSV), are an exciting new therapeutic strategy for cancer as they are replication competent in tumor cells but not normal cells. In order to engender herpes simplex virus with oncolytic activity and make it safe for clinical application, mutations are engineered into the virus ...
Ryuichi, Kanai, Samuel D, Rabkin
openaire +3 more sources
PLoS ONE, 2013 Despite intensive research efforts and therapeutic advances over the last few decades, the pediatric neural crest tumor, neuroblastoma, continues to be responsible for over 15% of pediatric cancer deaths. Novel therapeutic options are needed for this tumor.
Lauren A Gillory +11 more
openaire +4 more sources
Cell Reports MedicineSummary: Postoperative tumor recurrence represents a major challenge for patients. Oncolytic virus (OV) therapy has attracted increasing attention in recent years. Here, we construct a supramolecular hydrogel enabling extended release of type V oncolytic
Ciliang Guo +12 more
doaj +1 more source
Talimogene laherparepvec: First in class oncolytic virotherapy
Human Vaccines & Immunotherapeutics, 2018 Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at ...
Robert M. Conry +3 more
doaj +1 more source
Molecular Therapy: Oncolytics, 2017 Pediatric brain tumors including medulloblastoma and atypical teratoid/rhabdoid tumor are associated with significant mortality and treatment-associated morbidity.
Adam W. Studebaker +6 more
doaj +1 more source